Other substances

Quisinostat

A histone-deacetylase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Quisinostat is a hydroxamic acid-based histone deacetylase inhibitor with potential antineoplastic activity (NCIt). It has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia (DrugBank).

Quisinostat on PubChem
Quisinostat on Wikipedia

 

Structure image - Quisinostat

CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO

Supporting references

Link Tested on Impact factor Notes Publication date
Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment
in silico 2.08

In silico screening of ACE2 inhibitors.

 Jul/23/2020
Export (.csv)